ELF3

Summary

ELF3 (E74 like ETS transcription factor 3, HGNC:3318) is a protein-coding gene on chromosome 1q32.1, encoding ETS-related transcription factor Elf-3 (P78545). Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT].

Enables DNA-binding transcription activator activity, RNA polymerase II-specific and sequence-specific double-stranded DNA binding activity. Involved in inflammatory response; negative regulation of DNA-templated transcription; and positive regulation of transcription by RNA polymerase II. Located in nucleoplasm.

Source: NCBI Gene 1999 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 36 total
• Regional missense constraint (gnomAD): 1 of 3 regions constrained (≈4% of expected missense variation)
• GTEx eGene: eQTL in 8 tissues, sQTL in 1 (q < 0.05)
• Cancer driver (intOGen): activating (oncogene-like) across 3 cancer types (inferred from mutation patterns)
• Constraint (gnomAD): pLI 0.01 (LoF-tolerant), LOEUF 0.68 (unconstrained)
• Transcription factor: yes — 35 downstream targets (CollecTRI)
• MANE Select transcript: NM_004433

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3318
Approved symbol	ELF3
Name	E74 like ETS transcription factor 3
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	EPR-1, ESE-1, ERT
Ensembl gene	ENSG00000163435
Ensembl biotype	protein_coding
OMIM	602191
Entrez	1999

Gene structure

Transcript identifiers

Ensembl transcripts: 28 — 12 nonsense_mediated_decay, 10 protein_coding, 6 protein_coding_CDS_not_defined

MANE Select: ENST00000367284

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 3, TSL 2: 4, TSL 3: 1, TSL 5: 2

ENST00000367284, ENST00000359651, ENST00000367283, ENST00000446188, ENST00000470384, ENST00000475698, ENST00000479874, ENST00000490203, ENST00000495848, ENST00000498017, ENST00001004692, ENST00001004693, ENST00001004694, ENST00001004695, ENST00001004696, ENST00001004697, ENST00001004698, ENST00001056070, ENST00001056071, ENST00001056072, ENST00001056073, ENST00001056074, ENST00001056076, ENST00001056077, ENST00001056078, ENST00001120184, ENST00001125604, ENST00001145698

RefSeq mRNA: 2 — MANE Select: NM_004433 NM_001114309, NM_004433

CCDS: CCDS1419

Canonical transcript exons

ENST00000367284 — 9 exons

Exon	Start	End
ENSE00001074488	202013182	202013298
ENSE00001074490	202011957	202012178
ENSE00001074493	202012344	202012436
ENSE00001074503	202013829	202014024
ENSE00001708160	202010587	202010706
ENSE00003461023	202012947	202013036
ENSE00003493687	202011129	202011299
ENSE00003639455	202012640	202012759
ENSE00004807477	202015209	202017183

Expression profiles

Bgee: expression breadth ubiquitous, 197 present calls, max score 99.64.

FANTOM5 (CAGE): breadth broad, TPM avg 20.5917 / max 580.2913, expressed in 683 samples.

Highest expression (Bgee): lower esophagus mucosa, olfactory segment of nasal mucosa, mucosa of transverse colon, rectum, pancreatic ductal cell.

Genetic regulation across tissues (GTEx eQTL / sQTL)

ELF3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 8 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

9 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Whole Blood	eqtl	4.3e-09	+0.26	1:201987177:A:G
Breast Mammary Tissue	sqtl	6.9e-03	-1.25	1:202443905:A:C
Artery Coronary	eqtl	1.3e-02	+1.48	1:201513206:C:T
Cells Cultured fibroblasts	eqtl	1.6e-02	-0.20	1:201256834:T:G
Thyroid	eqtl	1.7e-02	-0.40	1:201680134:G:A
Brain Cerebellar Hemisphere	eqtl	1.7e-02	+0.30	1:201996727:C:T
Adipose Subcutaneous	eqtl	1.8e-02	+0.60	1:202003726:A:G
Pituitary	eqtl	3.7e-02	-0.83	1:201019241:A:AT
Esophagus Muscularis	eqtl	4.9e-02	-0.15	1:201200473:C:T

FANTOM5 promoters

3 alternative TSS:

Promoter ID	TPM avg	Samples expressed
7774	13.1501	570
7773	7.3974	630
7775	0.0441	22

Top tissues by expression

showing 100 of 252 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.64	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.60	gold quality
mucosa of transverse colon	UBERON:0004991	99.56	gold quality
rectum	UBERON:0001052	99.37	gold quality
pancreatic ductal cell	CL:0002079	99.03	gold quality
metanephros cortex	UBERON:0010533	98.95	gold quality
gall bladder	UBERON:0002110	98.77	gold quality
body of pancreas	UBERON:0001150	98.75	gold quality
minor salivary gland	UBERON:0001830	98.71	gold quality
esophagus mucosa	UBERON:0002469	98.55	gold quality
islet of Langerhans	UBERON:0000006	98.05	gold quality
pancreas	UBERON:0001264	97.75	gold quality
right uterine tube	UBERON:0001302	97.34	gold quality
palpebral conjunctiva	UBERON:0001812	96.89	gold quality
right lung	UBERON:0002167	96.86	gold quality
nasal cavity epithelium	UBERON:0005384	96.79	gold quality
upper lobe of left lung	UBERON:0008952	96.50	gold quality
oviduct epithelium	UBERON:0004804	96.37	gold quality
epithelial cell of pancreas	CL:0000083	96.29	gold quality
right lobe of liver	UBERON:0001114	95.93	gold quality
saliva-secreting gland	UBERON:0001044	95.80	gold quality
fallopian tube	UBERON:0003889	95.31	gold quality
left uterine tube	UBERON:0001303	95.30	gold quality
mouth mucosa	UBERON:0003729	95.23	gold quality
mucosa of stomach	UBERON:0001199	94.92	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.80	gold quality
upper lobe of lung	UBERON:0008948	94.56	gold quality
transverse colon	UBERON:0001157	94.33	gold quality
vagina	UBERON:0000996	93.61	gold quality
nasal cavity mucosa	UBERON:0001826	93.25	gold quality
small intestine	UBERON:0002108	93.20	gold quality
bronchial epithelial cell	CL:0002328	93.14	gold quality
bronchus	UBERON:0002185	92.94	gold quality
prostate gland	UBERON:0002367	92.80	gold quality
ileal mucosa	UBERON:0000331	92.79	gold quality
urinary bladder	UBERON:0001255	92.65	gold quality
adult mammalian kidney	UBERON:0000082	92.52	gold quality
trachea	UBERON:0003126	92.07	gold quality
body of stomach	UBERON:0001161	91.72	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.46	gold quality
stomach	UBERON:0000945	91.29	gold quality
colonic mucosa	UBERON:0000317	91.26	gold quality
amniotic fluid	UBERON:0000173	91.09	gold quality
duodenum	UBERON:0002114	90.79	gold quality
epithelium of nasopharynx	UBERON:0001951	90.51	gold quality
colonic epithelium	UBERON:0000397	90.29	gold quality
mucosa of sigmoid colon	UBERON:0004993	90.01	gold quality
vermiform appendix	UBERON:0001154	89.99	gold quality
skin of abdomen	UBERON:0001416	88.85	gold quality
lung	UBERON:0002048	88.80	gold quality
skin of leg	UBERON:0001511	88.61	gold quality
intestine	UBERON:0000160	88.49	gold quality
cortex of kidney	UBERON:0001225	86.92	gold quality
large intestine	UBERON:0000059	86.87	gold quality
esophagus squamous epithelium	UBERON:0006920	86.80	gold quality
caecum	UBERON:0001153	86.77	gold quality
kidney	UBERON:0002113	86.66	gold quality
colon	UBERON:0001155	86.57	gold quality
tonsil	UBERON:0002372	86.31	gold quality
urethra	UBERON:0000057	85.50	gold quality
fundus of stomach	UBERON:0001160	84.91	gold quality
zone of skin	UBERON:0000014	84.56	gold quality
liver	UBERON:0002107	84.26	gold quality
endocervix	UBERON:0000458	83.37	gold quality
sperm	CL:0000019	83.02	gold quality
esophagus	UBERON:0001043	83.01	gold quality
metanephros	UBERON:0000081	81.82	gold quality
right lobe of thyroid gland	UBERON:0001119	81.77	gold quality
left lobe of thyroid gland	UBERON:0001120	81.54	gold quality
adenohypophysis	UBERON:0002196	81.31	gold quality
buccal mucosa cell	CL:0002336	81.04	gold quality
pharyngeal mucosa	UBERON:0000355	80.83	gold quality
pylorus	UBERON:0001166	80.55	gold quality
epithelium of mammary gland	UBERON:0003244	80.27	gold quality
thyroid gland	UBERON:0002046	80.18	gold quality
mammary duct	UBERON:0001765	80.11	gold quality
jejunal mucosa	UBERON:0000399	79.35	gold quality
mammary gland	UBERON:0001911	79.03	gold quality
thoracic mammary gland	UBERON:0005200	78.90	gold quality
uterine cervix	UBERON:0000002	78.74	gold quality
endometrium	UBERON:0001295	78.63	gold quality
cartilage tissue	UBERON:0002418	78.29	gold quality
parotid gland	UBERON:0001831	77.95	gold quality
smooth muscle tissue	UBERON:0001135	77.48	gold quality
granulocyte	CL:0000094	76.90	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.84	gold quality
ectocervix	UBERON:0012249	76.32	gold quality
pituitary gland	UBERON:0000007	75.99	gold quality
oral cavity	UBERON:0000167	75.96	gold quality
kidney epithelium	UBERON:0004819	75.76	silver quality
caput epididymis	UBERON:0004358	74.13	gold quality
muscle layer of sigmoid colon	UBERON:0035805	73.41	gold quality
female reproductive system	UBERON:0000474	73.24	gold quality
lower lobe of lung	UBERON:0008949	72.99	silver quality
renal medulla	UBERON:0000362	72.20	gold quality
gingival epithelium	UBERON:0001949	72.18	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	71.63	gold quality
uterus	UBERON:0000995	70.61	gold quality
gingiva	UBERON:0001828	69.90	gold quality
cauda epididymis	UBERON:0004360	69.88	gold quality

Single-cell (SCXA)

Detected in 31 experiment(s), a significant marker in 29.

Experiment	Marker?	Max mean expression
E-MTAB-8495	yes	5498.68
E-ANND-2	yes	4651.82
E-GEOD-81547	yes	3981.70
E-CURD-122	yes	3036.51
E-MTAB-8221	yes	2703.94
E-MTAB-9906	yes	2569.91
E-MTAB-8530	yes	2566.05
E-GEOD-124472	yes	2348.57
E-CURD-88	yes	2261.36
E-MTAB-8410	yes	2068.15
E-GEOD-114530	yes	1919.80
E-HCAD-10	yes	1802.01
E-HCAD-15	yes	1314.14
E-MTAB-6308	yes	1268.94
E-MTAB-10287	yes	1163.77

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 63 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Urinary bladder	tissue	154.3	high
Colon	tissue	151.3	medium
Small intestine	tissue	137.1	medium
Duodenum	tissue	134.6	medium
Esophagus	tissue	131.3	not detected
Rectum	tissue	119.9	medium
Stomach 1	tissue	115.8	low
Pancreas	tissue	113.9	low
Vagina	tissue	92.2	low
Salivary gland	tissue	79.6	medium
Gallbladder	tissue	72.9	medium
Lung	tissue	35.0	not detected
Fallopian tube	tissue	33.5	low
Breast	tissue	29.2	not detected
Cervix	tissue	25.6	low
Liver	tissue	24.1	not detected
Prostate	tissue	21.8	not detected
Kidney	tissue	19.1	low
Tonsil	tissue	15.0	high
Seminal vesicle	tissue	14.0	low
Endometrium 1	tissue	12.1	high
Appendix	tissue	12.0	medium
Parathyroid gland	tissue	7.9	low
Smooth muscle	tissue	6.8	not detected
Placenta	tissue	5.7	medium
Epididymis	tissue	4.3	not detected
Pituitary gland	tissue	3.7
Thyroid gland	tissue	2.4	not detected
Postcentral gyrus	tissue	2.3
Choroid plexus	tissue	2.1
Skin 1	tissue	1.6	not detected
Hippocampus	tissue	1.6	not detected
Adipose tissue	tissue	1.5	not detected
Thymus	tissue	1.5
Nucleus accumbens	tissue	1.4
Locus coeruleus	tissue	1.3
Basal ganglia	tissue	1.1	not detected
Retina	tissue	0.9
Putamen	tissue	0.9
Bone marrow	tissue	0.7	not detected
Hippocampal formation	tissue	0.7
Ventral forebrain	tissue	0.7
Superior colliculi	tissue	0.5
Lymph node	tissue	0.3	not detected
Heart muscle	tissue	0.2	not detected
Pons	tissue	0.2
Spleen	tissue	0.2	not detected
Spinal cord	tissue	0.2
Olfactory bulb	tissue	0.2
Septum	tissue	0.2
Testis	tissue	0.1	not detected
Ovary	tissue	0.1	not detected
Skeletal muscle	tissue	0.1	not detected
Midbrain	tissue	0.1
Medulla oblongata	tissue	0.1
Thalamus	tissue	0.1
Hypothalamus	tissue	0.1
Substantia nigra	tissue	0.1
Adrenal gland	tissue	0.1	not detected
Periaqueductal gray	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 188; highest nTPM — Flocculonodular lobe (3.1), Vermis (3.0), Cerebellar cortex (2.5), Parietal operculum (2.4), Frontal eye field (2.3).

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

showing 30 of 35 targets:

Target	Regulation
ANGPT1
AR
CCL20	Unknown
CCND3
CLDN7	Unknown
COL2A1
EGR1	Unknown
EHF	Activation
ERBB2
FOLH1
FOXC1
GADD45GIP1
HP
IL1B
KLK3
KRT4	Repression
KRT8
LYZ	Activation
MED23
MMP13	Unknown
MMP9	Repression
NOS2
NOTCH3
POU5F1	Unknown
PRR9	Unknown
PTGS2	Unknown
SPRR1A	Unknown
SPRR1B	Activation
SPRR2A	Activation
SPRR3	Unknown

JASPAR motifs

Motif	Name	Family
MA0640.1	ELF3	Ets-related
MA0640.2	ELF3	Ets-related
MA0640.3	ELF3	Ets-related

JASPAR matrix evidence (PMIDs): PMID:20517297, PMID:9234700

Upstream regulators (CollecTRI, top): AR, FOXA1, KDM5B, NFKB1, NFKB, RELA

miRNA regulators (miRDB)

Targeting ELF3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 84 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-6764-5P	99.75	67.89	2304

Functional genomics

gnomAD constraint: pLI 0.015, LOEUF 0.678, missense Z 2.01 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000367284 splits into 3 regions with different missense tolerance; 1 is missense-constrained (≈4% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
1:202,011,137–202,013,834	311 / 351.2	0.89	no
1:202,013,835–202,013,879	1 / 20.6	0.05	yes (p 1.6e-05)
1:202,013,880–202,015,320	61 / 115.9	0.53	no

Literature-anchored findings (GeneRIF, showing 40)

• ErbB2 activation of ESX gene expression (PMID:12032832)
• ESX regulates HER2 expression by binding to DRIP130 (PMID:12242338)
• co-ordinate activation and binding of ESE-1, Sp1, and NF-kappaB to the MIP-3alpha promoter is required for maximal gene expression by cytokine-stimulated Caco-2 human intestinal epithelial cells. (PMID:12414801)
• Ese-1 binds with Skn-1a in human cells (PMID:12624109)
• ERT mediates the expression of TGF-beta RII, and the transcriptional inhibition of ets-related transcription factor could be a one of the mechanisms of colonic carcinogenesis (PMID:14582709)
• results support a role for the ETS factor ESE-1 as a novel transcriptional regulator of angiopoietin-1 gene regulation in the setting of inflammation (PMID:14715662)
• ESX expression alone confers a transformed and in vitro metastatic phenotype to otherwise normal MCF-12A cells (PMID:14767472)
• activity of ESE-1 is positively and negatively modulated by other interacting proteins including Ku70, Ku86, p300, and CBP. (PMID:15075319)
• stably expressed green fluorescent protein-ESE-1 transforms MCF-12A human mammary epithelial cells; and the ESE-1 SAR domain, acting in the cytoplasm, is necessary and sufficient to mediate this transformation (PMID:15169914)
• the induction of claudin7 expression by ELF3 appears critical to the formation of the epithelial structures in biphasic synovial sarcoma (PMID:17060315)
• AT-hook domain, as well as serine- and aspartic acid-rich domain but not the pointed domain, is necessary for Elf3 activation of promoter activity. (PMID:17148437)
• ESE-1 functions are coordinately regulated by Pak1 phosphorylation and beta-TrCP-dependent ubiquitin-proteasome pathways. (PMID:17491012)
• Intracellular ESE-1 staining in chondrocytes in cartilage from patients with osteoarthritis, but not in normal cartilage, further suggests a fundamental role for ESE-1 in cartilage degeneration and suppression of repair. (PMID:18044710)
• ESE-1 negatively regulates the invasion of oral squamous cell carcinoma via transcriptional suppression of MMP-9. (PMID:18302674)
• ESE-1 and ESE-3 play an important role in airway inflammation. (PMID:18475289)
• activation of ESE-1 via enhanced nuclear translocation mediates tolfenamic acid-induced EGR-1 expression, which plays a critical role in the activation of apoptosis (PMID:19074849)
• ESE-1 contains signal sequences that play a critical role in regulating its subcellular localization and function, and that an intact SAR domain mediates mammary epithelial cell transformation exclusively in the cytoplasm (PMID:21871131)
• a novel role for ELF3 as a procatabolic factor that may contribute to cartilage remodeling and degradation by regulating MMP13 gene transcription. (PMID:22158614)
• ELF3 and CEA expression showed statistically significant differences among four lymph node groups: lymph nodes from patients with colorectal cancer categorized into three Dukes’ stages and LNs from patients with ulcerative colitis. (PMID:22993316)
• Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. (PMID:23329352)
• The physical interaction between ELF3 and androgen receptor (AR) inhibits the recruitment of AR to specific androgen response elements within target gene promoters. (PMID:23435425)
• The concordant upregulation of ESE1/ELF3 and NF-kappaB in human prostate tumors. (PMID:23687337)
• ELF3 is a candidate transcriptional regulator involved in human urothelial cytodifferentiation. (PMID:24374157)
• data suggest that polyomavirus enhancer activator 3 and epithelium-specific transcription factor-1 may play important roles in pluri potent and tumorigenic embryonic carcinoma cells. (PMID:24694612)
• data identify Elf3 as a pivotal driver for beta-catenin signaling in CRC, and highlight potential prognostic and therapeutic significance of Elf3 in CRC. (PMID:24874735)
• ESE-1 actS as an upstream effector to regulate OCT4 transcription in NCCIT pluripotent embryonic carcinoma cells. (PMID:24971534)
• our data suggested that ESE1/ELF3 may promote the UC progression via accelerating NF-kappaB activation and thus facilitating IEC apoptosis. (PMID:25926267)
• suggest that ESE-1 may play a role in regulating airway inflammation by regulating ICAM-1 expression (PMID:26185364)
• ELF3 is a frequently mutated tumor suppressor gene of periampullary tumors. (PMID:26804919)
• ELF3 is a novel transcriptional repressor of estrogen receptor alpha in breast cancer cells. (PMID:26920025)
• data suggest that interactions between ESE1 and beta-/alpha-catenins might be a mechanism by which the ESE1 protein determines the beta-catenin function and tumorigenesis (PMID:27272778)
• ELF3 interacts directly with the HMG domain of Sox9. Importantly, overexpression of ELF3 significantly decreased Sox9/CBP-dependent HAT activity. (PMID:27310669)
• These findings position RIPK4 upstream of a hierarchal IRF6-GRHL3-ELF3 transcription factor pathway in keratinocytes. (PMID:27667567)
• Survival analysis showed that the non-small cell lung carcinoma patients with enhanced expression of CK7, ELF3, EGFR, and EphB4 mRNA in peripheral blood leukocytes had poorer disease-free survival and overall survival than those without. (PMID:27827952)
• Data indicate that the transcription factor E74-like factor 3 (ELF3) was one of the genes whose expression was upregulated in microdissected ovarian cancer cells of long-term survivors. (PMID:28199976)
• Epithelium-specific ETS transcription factor 1 (ESE1), a member of the Ets transcription factor family. (PMID:28247944)
• Data suggest ESE-1 silencing as a mean to treat HER2(+) patients who show resistance to anti-HER2 therapy. (PMID:29187433)
• Data suggest that ELF3 is up-regulated at mRNA and protein levels in NSCLC (non-small cell lung cancer) tissues compared to corresponding control lung tissue; expression level of ELF3 is correlated with overall survival of patients with NSCLC. (PMID:29208568)
• ELF3 knockdown reversed epithelial-mesenchymal transition via repressing ZEB1 expression through miR-141-3p upregulation. (PMID:29523781)
• Leptin synergizes with IL-1beta in inducing ELF3 expression in chondrocytes. (PMID:29550824)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	elf3	ENSDARG00000077982
mus_musculus	Elf3	ENSMUSG00000003051
rattus_norvegicus	Elf3	ENSRNOG00000006330

Paralogs (28): ETV1 (ENSG00000006468), ETV7 (ENSG00000010030), SPI1 (ENSG00000066336), ELF4 (ENSG00000102034), ETV2 (ENSG00000105672), ERF (ENSG00000105722), ELF2 (ENSG00000109381), ELK3 (ENSG00000111145), ETV3 (ENSG00000117036), ELF1 (ENSG00000120690), SPDEF (ENSG00000124664), ELK1 (ENSG00000126767), ETS1 (ENSG00000134954), EHF (ENSG00000135373), ELF5 (ENSG00000135374), ETV6 (ENSG00000139083), FLI1 (ENSG00000151702), GABPA (ENSG00000154727), ERG (ENSG00000157554), ETS2 (ENSG00000157557), ELK4 (ENSG00000158711), FEV (ENSG00000163497), SPIC (ENSG00000166211), ETV4 (ENSG00000175832), ETV5 (ENSG00000244405), ETV3L (ENSG00000253831), ERFL (ENSG00000268041), SPIB (ENSG00000269404)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1101781) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 10 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal enterocyte morphology	1
abnormal intestinal epithelium morphology	1
decreased body size	1
abnormal intestine goblet cell morphology	1
diarrhea	1
cachexia	1
lethargy	1
postnatal lethality, incomplete penetrance	1
embryonic lethality during organogenesis, incomplete penetrance	1
preweaning lethality, incomplete penetrance	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Drosophila melanogaster	P11536	99.8%	Diamond
Pan paniscus	A1YG61	99.7%	Diamond
Pan troglodytes	A2T737	99.7%	Diamond
Gorilla gorilla gorilla	A1YF15	99.6%	Diamond
Gallus gallus	P13474	99.5%	Diamond
Xenopus laevis	P18755	98.5%	Diamond
Bos taurus	Q2KIC2	98.1%	Diamond
Ateles geoffroyi	A2D4Z7	97.5%	Diamond
Sus scrofa	Q6PKU1	96.7%	Diamond
Lytechinus variegatus	P29773	93.8%	Diamond
Caenorhabditis elegans	Q18579	87.2%	Diamond
Drosophila virilis	Q7M3M6	79.6%	Diamond
Paleosuchus palpebrosus	Q9I8M6	65.2%	Diamond
Avian leukemia virus e26	P01105	99.4%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
ELF3-AS1	ncRNA	102723465
SNORA70H	snoRNA	109616993
RNPEP	protein-coding	6051
MIR6740	ncRNA	102465443
ARL8A	protein-coding	127829
PTPN7	protein-coding	5778
GPR37L1	protein-coding	9283
TIMM17A	protein-coding	10440

Protein

Protein identifiers

ETS-related transcription factor Elf-3 — P78545 (reviewed: P78545)

Alternative names: E74-like factor 3, Epithelial-restricted with serine box, Epithelium-restricted Ets protein ESX, Epithelium-specific Ets transcription factor 1

All UniProt accessions (5): P78545, A0A8E8R951, A0A8E8R9T1, A0A8E8V1S5, Q5SR36

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. May be a critical downstream effector of the ERBB2 signaling pathway. May be associated with mammary gland development and involution. Plays an important role in the regulation of transcription with TATA-less promoters in preimplantation embryos, which is essential in preimplantation development.

Subunit / interactions. Interacts with TBP. Interacts with CREBBP and EP300; these act as transcriptional coactivators of ELF3 and positively modulate its function. Interacts with XRCC5/KU86 and XRCC6/KU70; these inhibit the ability of ELF3 to bind DNA and negatively modulate its transcriptional activity. Associated with CLND7 and POU2F3. Interacts with ZNF768.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expressed exclusively in tissues containing a high content of terminally differentiated epithelial cells including mammary gland, colon, trachea, kidney, prostate, uterus, stomach and skin.

Domain organisation. The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Induction. Transcriptionally regulated by ERBB2 receptor signaling in breast cancer epithelial cells. Up-regulated by phorbol 12-myristate 13-acetate (PMA) in bronchial epithelial cells. By retinoic acid in MCF-7 mammary epithelial cells (at protein level).

Similarity. Belongs to the ETS family.

Isoforms (2)

UniProt ID	Names	Canonical?
P78545-1	1, ESE-1b	yes
P78545-2	2, ESE-1a

RefSeq proteins (2): NP_001107781, NP_004424* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000418	Ets_dom	Domain
IPR003118	Pointed_dom	Domain
IPR013761	SAM/pointed_sf	Homologous_superfamily
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR042693	Elf-3_PNT	Domain
IPR046328	ETS_fam	Family

Pfam: PF00178, PF02198

UniProt features (33 total): sequence conflict 11, helix 6, mutagenesis site 4, compositionally biased region 3, chain 1, domain 1, DNA-binding region 1, strand 1, turn 1, region of interest 1, short sequence motif 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures by resolution:

PDB	Title	Method	Resolution (Å)
2E8P	Solution structure of the N-terminal SAM-domain of E74-like factor 3	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P78545-F1	66.32	0.20

Human Protein Atlas

Protein class: Predicted intracellular proteins, Transcription factors, Helix-turn-helix domains, Cancer-related genes, Mutated cancer genes, Mutational cancer driver genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm

Antibody reliability (HPA): IH enhanced · IF enhanced

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (4)

Position	Phenotype
247–250	no effect on transcriptional repression on krt4 promoter.
315	partially abrogates repressive effect on the krt4 promoter; when associated with a-319.
319	partially abrogates repressive effect on the krt4 promoter; when associated with a-315.
334–337	partially abrogates repressive effect on the krt4 promoter.

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 4; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

4 pathways:

ID	Pathway	Evidence
R-HSA-1912408	Pre-NOTCH Transcription and Translation	curated
R-HSA-1912422	Pre-NOTCH Expression and Processing	—
R-HSA-162582	Signal Transduction	—
R-HSA-157118	Signaling by NOTCH	—

MSigDB gene sets: 220 (showing top): REACTOME_SIGNALING_BY_NOTCH, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_MAMMARY_GLAND_MORPHOGENESIS, GOBP_GLAND_MORPHOGENESIS, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_INFLAMMATORY_RESPONSE, SCHWAB_TARGETS_OF_BMYB_POLYMORPHIC_VARIANTS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, TGACCTY_ERR1_Q2, HATADA_METHYLATED_IN_LUNG_CANCER_DN, MODULE_66, BORLAK_LIVER_CANCER_EGF_UP, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN

GO Biological Process (8): DNA-templated transcription (GO:0006351), regulation of transcription by RNA polymerase II (GO:0006357), inflammatory response (GO:0006954), cell differentiation (GO:0030154), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), mammary gland involution (GO:0060056), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (8): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA-binding transcription factor activity (GO:0003700), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737)

Reactome top-level categories

3 top-level categories:

Category	Pathways
Pre-NOTCH Expression and Processing	1
Signal Transduction	1
Signaling by NOTCH	1

GO top-level categories

33 GO namespaces:

Category	Terms
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
transcription by RNA polymerase II	2
DNA-templated transcription	2
regulation of transcription by RNA polymerase II	2
gene expression	1
RNA biosynthetic process	1
defense response	1
cellular developmental process	1
negative regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
tissue remodeling	1
mammary gland morphogenesis	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
nucleic acid binding	1
binding	1
DNA binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 6 of 20 annotations. The rest are phylogenetic / computational / electronic (IEA).

6 experimentally-supported GO terms:

GO term	NS	Evidence
inflammatory response	BP	expression pattern
negative regulation of DNA-templated transcription	BP	direct assay
positive regulation of transcription by RNA polymerase II	BP	direct assay
nucleoplasm	CC	direct assay
DNA-binding transcription activator activity, RNA polymerase II-specific	MF	direct assay
sequence-specific double-stranded DNA binding	MF	direct assay

Protein interactions and networks

STRING

showing 16 of 1,264 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ELF3	SPRR2A	P35326	783
ELF3	POU2F3	Q9UKI9	740
ELF3	ESX1	Q8N693	718
ELF3	CCL20	P78556	651
ELF3	SPTBN1	Q01082	610
ELF3	SPTB	P11277	557
ELF3	EPHB2	P29323	547
ELF3	ELF4	Q99607	540
ELF3	TYRO3	Q06418	499
ELF3	PRR9	Q5T870	492
ELF3	POU2F2	P09086	432
ELF3	WFDC5	Q8TCV5	429
ELF3	ARL8A	Q96BM9	407
ELF3	PIK3CA	P42336	402
ELF3	TBP	P20226	401
ELF3	ARID1A	O14497	401

IntAct

Human interaction partners of ELF3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

showing 30 of 46 partners by confidence:

Partner	Interaction type	MIscore	Records
NFE2L2	physical association	0.580	5
RELA	physical association	0.460	2
PRKCI	physical association	0.400	2
APBA3	physical association	0.370	1
CCL2	physical association	0.370	1
CCL24	physical association	0.370	1
IL23A	physical association	0.370	1
IL36A	physical association	0.370	1
UBE2D1	physical association	0.370	1
UBE2D2	physical association	0.370	1
NOTCH3	association	0.350	1
RSL1D1	association	0.350	1
SMARCA4	proximity	0.270	4
FBXW7	proximity	0.270	2
AKT1	proximity	0.270	1
PTEN	proximity	0.270	1
SPOP	proximity	0.270	1
TP53	proximity	0.270	1
TRIM24	proximity	0.270	1
AKAP9	physical association	0.000	1
ATIC	physical association	0.000	1
CALR	physical association	0.000	1
EEF1D	physical association	0.000	1
EHF	physical association	0.000	1
ETFA	physical association	0.000	1
EWSR1	physical association	0.000	1
FSCN1	physical association	0.000	1
GANAB	physical association	0.000	1
GARS1	physical association	0.000	1
H2BC10	physical association	0.000	1

BioGRID (68 interactions; top human partners by supporting records): MED23 (Reconstituted Complex; 6 records), NFKB1 (Affinity Capture-Western; 3 records), AR (Affinity Capture-Western; 2 records), EP300 (Affinity Capture-MS; 2 records), GADD45GIP1 (Affinity Capture-Western; 2 records), NFE2L2 (Two-hybrid; 2 records), PAK1 (Biochemical Activity; 2 records), XRCC5 (Affinity Capture-MS; 2 records), XRCC6 (Affinity Capture-MS; 2 records), AIMP1 (Affinity Capture-MS), ATIC (Affinity Capture-MS), BTRC (Affinity Capture-Western), CALR (Affinity Capture-MS), CBR3 (Affinity Capture-MS), CECR2 (Affinity Capture-MS)

SIGNOR signaling

4 signaling interactions:

A	Effect	B	Mechanism
PAK1	up-regulates	ELF3	phosphorylation
ELF3	“down-regulates quantity by repression”	KRT4	“transcriptional regulation”
ELF3	“up-regulates quantity by expression”	SPRR2A	“transcriptional regulation”
ELF3	“up-regulates quantity by expression”	SPRR1B	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 46 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
KEAP1-NFE2L2 pathway	6	17.6×	5e-04
Cellular response to chemical stress	5	17.4×	2e-03
Downstream TCR signaling	5	15.7×	3e-03
Interleukin-4 and Interleukin-13 signaling	5	12.6×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
proteasome-mediated ubiquitin-dependent protein catabolic process	7	8.1×	5e-03
positive regulation of gene expression	8	6.9×	5e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 3 cancer types — BLCA, CHOL, COADREAD.

intOGen’s role is a computational inference from cohort mutation patterns and may diverge from the gene’s curated/literature role; read it alongside the evidence above.

Genetic variants

Variant evidence for ELF3: 36 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	3
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 31 predictions of 631):

Position(s)	Effect	Δscore	Sites
1:202011127–202011128	acceptor_loss	1.0000	6
1:202011300–202011301	donor_loss	1.0000	5
1:202011945	acceptor_gain	1.0000
1:202011956	acceptor_loss	1.0000	2
1:202012121	donor_gain	1.0000
1:202012166	donor_gain	1.0000
1:202012179–202012180	donor_loss	1.0000	3
1:202012225	donor_gain	1.0000
1:202012342–202012343	acceptor_loss	1.0000	6
1:202012437–202012438	donor_loss	1.0000	5

AlphaMissense

775 missense substitutions predicted likely pathogenic (of 2,454 scored), across 173 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M324	9	0.998	1.000
M333	9	0.963	0.999
F303	8	0.998	1.000
S330	8	0.997	1.000
F354	8	0.996	1.000
F305	8	0.993	1.000
N321	8	0.991	0.999
F278	8	0.988	1.000
H274	8	0.987	1.000
D281	8	0.955	0.995
F114	8	0.942	0.988
D346	8	0.936	0.983
N357	8	0.844	0.961
W295	7	1.000	1.000
W315	7	1.000	1.000
W276	7	0.999	1.000
E327	7	0.999	1.000
R334	7	0.999	1.000
W361	7	0.995	0.999
K328	7	0.994	1.000

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Disease associations

OMIM: gene MIM:602191 | disease phenotypes:

GWAS associations

1 associations:

Study	Trait	p-value
GCST011956_94	Systemic lupus erythematosus	4e-9

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2111426 (PROTEIN-PROTEIN INTERACTION)

PharmGKB: 1 entry (CPIC guideline: no)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.23	Kd	590	nM	CHEMBL1077445
6.21	Kd	620	nM	CHEMBL1077474
6.00	Kd	1000	nM	CHEMBL1077454
5.23	Kd	5900	nM	CHEMBL1077475

PubChem BioAssay actives

4 with measured affinity, of 14 total; 4 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-[[(3S,5R)-3-(2-hydroxyethyl)-3-(2-methylpropyl)-2-[[4-(trifluoromethyl)phenyl]methyl]-1,2-oxazolidin-5-yl]methylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid	469608: Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression by Western blotting	kd	0.5900	uM
5-[[(3S,5R)-3-(2-hydroxyethyl)-3-(2-methylpropyl)-2-[(4-phenylphenyl)methyl]-1,2-oxazolidin-5-yl]methylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid	469608: Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression by Western blotting	kd	0.6200	uM
5-[[(3S,5R)-3-(2-hydroxyethyl)-3-(2-methylpropyl)-2-(naphthalen-2-ylmethyl)-1,2-oxazolidin-5-yl]methylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid	469608: Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression by Western blotting	kd	1.0000	uM
5-[[(3S,5R)-2-benzyl-3-(2-hydroxyethyl)-3-(2-methylpropyl)-1,2-oxazolidin-5-yl]methylcarbamothioylamino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid	469608: Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression by Western blotting	kd	5.9000	uM

CTD chemical–gene interactions

93 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, decreases expression, increases methylation, affects cotreatment	6
sodium arsenite	affects cotreatment, increases abundance, decreases expression	4
Air Pollutants	decreases expression, increases abundance, increases expression	4
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	4
Estradiol	decreases expression, affects expression, increases reaction, affects cotreatment	4
Tetrachlorodibenzodioxin	increases expression	4
trichostatin A	affects cotreatment, increases expression	3
perfluorooctane sulfonic acid	decreases expression, increases expression	3
Calcitriol	decreases expression, increases expression, affects cotreatment	3
Smoke	decreases expression, increases abundance, increases expression	3
Particulate Matter	decreases expression, increases abundance, increases expression, affects cotreatment	3
methylselenic acid	affects expression, increases expression	2
entinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Microplastics	increases abundance, decreases expression	2
Ethanol	affects cotreatment, increases expression, increases abundance	2
Cisplatin	affects expression, affects cotreatment, increases expression	2
Formaldehyde	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Testosterone	affects cotreatment, increases expression, decreases expression	2
Tretinoin	increases expression	2
Fenretinide	increases expression	2
Raloxifene Hydrochloride	affects cotreatment, decreases expression, increases expression	2
aristolochic acid I	increases expression	1
Glupearl 19S	increases expression	1
TAK-243	increases sumoylation	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
lead acetate	decreases expression	1
arsenite	decreases expression, increases abundance	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1099983	Binding	Inhibition of ESX-Med23 interaction in human BT474 cells assessed as down regulation of ErbB2 expression up to 50 uM by Western blotting	Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics. — *Bioorg Med Chem Lett*

Cellosaurus cell lines

6 cell lines: 3 embryonic stem cell, 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1H2	SEES3-1V human ELF3, clone1	Embryonic stem cell	Male
CVCL_A1H3	SEES3-1V human ELF3, clone2	Embryonic stem cell	Male
CVCL_A1H4	SEES3-1V human ELF3, clone3	Embryonic stem cell	Male
CVCL_D7PB	Ubigene A-549 ELF3 KO	Cancer cell line	Male
CVCL_D9E8	Ubigene HEK293 ELF3 KO	Transformed cell line	Female
CVCL_E0CK	Ubigene HeLa ELF3 KO	Cancer cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for ELF3 across ~30M SureChEMBL compounds — explore on Sugi Predict.